Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
2.430
-0.070 (-2.80%)
Oct 30, 2024, 4:00 PM EDT - Market closed
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
16.99M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cumberland Pharmaceuticals | 37.79M |
Marinus Pharmaceuticals | 30.26M |
T2 Biosystems | 7.16M |
HCW Biologics | 3.92M |
Synlogic | 3.17M |
GeoVax Labs | 300.68K |
Kazia Therapeutics | 382.00 |
NERV News
- 6 months ago - Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 8 months ago - US FDA declines to approve Minerva Neurosciences' schizophrenia drug - Reuters
- 8 months ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences: There's Probably Time For One More Rally - Seeking Alpha
- 1 year ago - Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market - GlobeNewsWire
- 1 year ago - Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead - Seeking Alpha